Earlier MSA detection could guide alpha-synuclein drug discovery - Drug Target Review
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
MSA and Parkinson’s share alpha-synuclein pathology but progress very differently. Earlier detection could help researchers understand why – and reveal which proteins, cells and disease mechanisms offer the strongest therapeutic targets. Multiple system atrophy (MSA) is a devastating condition that progresses rapidly, leaving patients and families to navigate an uncertain future. The rare neurodegenerative disorder is often fatal within five years and affects voluntary and involuntary functions, including movement, balance and even digestion or blood pressure regulation. A treatment that slows disease progression could mean more time for patients to remain independent, make plans and be with the people they love.
MSA, Parkinson’s disease and Lewy body dementia (LBD) share an association with misfolded alpha-synuclein protein. And yet, for example, MSA patients do not respond well to standard Parkinson’s therapies. For drug discovery researchers, the disease raises questions that reach beyond MSA: why does pathology involving the same protein behave so differently across neurodegenerative conditions? Which differences should determine what a drug targets?
This article is an excerpt. To read the full content, visit the original source. Drug Target Review
Related articles
ccRCC kidney cancer: PET/CT imaging approach improves lesion detection - healthcare-in-europe.com
Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice - Nature
AcknowledgementsThe authors thank Arcus Biosciences for providing AB680 and AB928 for the experiments. This research was supported [in part] by the Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute, CCR, CIL. The contributions of the NIH authors (S. T., C. I. K. C., F. J. G.) were made as part of their official duties as NIH federal employees, are in compliance with agency policy requirements, and are considered Works of the United States Government. However, the findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U. S. Department of Health and Human Services. Schematic diagrams (Figs. 1A, E, 2A, E, 5D, 6A, D and 7A, G) were created with BioRender.com. FundingThis work was funded by NIH grants R01CA148828, R01CA245546, R01DK095201, and UMCCC Core Grant P30CA046592 (Y. M. S.). R01AI152517 to C. A. P. R01CA248160 to C. A. L. R. S. was supported by a Postdoctoral Fellowship (032650) from the American Physiological Society and a Research Fellow Award (1003279) from the Crohn’s and Colitis Foundation. N. W. Z.
RSV Linked to Severe Complications After Lung Transplant - EMJ
RSV IN lung transplant recipients was associated with respiratory failure, declining lung function, and mortality in hospitalized patients. An international multicenter study of 155 adult lung transplant recipients hospitalized with respiratory syncytial virus (RSV) infection identified clinical predictors of severe complications, highlighting the importance of early assessment and continued monitoring in this vulnerable population.
0 comments
No comments yet. Be the first to share your thoughts!